by Douglas O. Sobel  and Keerat Parmar

Received: 31 August 2025;  Published: 14 April 2026;  doi: 10.21926/obm.transplant.2602269

Subcutaneous transplantation of islets into small-pore macroencapsulation devices that prevent immune cell passage can inhibit allorejection in rodents. However, there are no reports of euglycemia in humans using this technology. This report further develops these macroencapsulation devices. We compared the ability of macroencapsulation transplant devices containing transformed mouse islet cells (MIN-6) with varying polymer membranes, pore sizes, and hydrophilicity to inhibit allorejection and maintain glycemic con [...]

by Douglas Sobel  and Wanxing Cui

Received: 09 October 2025;  Published: 20 March 2026;  doi: 10.21926/obm.transplant.2601268

Transplanting islets into the subcutaneous (SC) space rather than the portal vein is advantageous because this site is easier and safer to use. However, transplantation of islets directly or within planar devices has been unsuccessful in humans, mainly because of the low oxygen torr in the SC space. Since human islets are very different from mouse islets, the use of human islets in animal experiments to study SC islet transplantation may help to alleviate the roadblocks of this approach in humans. This is the first [...]

by Alisia Chen  and Jeong M. Park

Received: 29 October 2025;  Published: 24 February 2026;  doi: 10.21926/obm.transplant.2601267

Antibody mediated rejection (AMR) is a considerable cause of late allograft failure in solid organ transplantation. Conventional approaches, using plasmapheresis, intravenous immunoglobulin, rituximab, bortezomib, and eculizumab have been unsuccessful in improving graft survival. This review aims to assess emerging therapies for AMR treatment across all organs. Using a PubMed search, literature published up to July 20, 2025 regarding tocilizumab, clazakizumab, carfilzomib, daratumumab, imlifidase, felzartamab, and [...]

by Mohammed H. Moghadasian

Received: 27 January 2026;  Published: 12 February 2026;  doi: 10.21926/obm.transplant.2601266

Dietary guidelines and Nutrient Reference Intakes are important tools for maintaining optimal health in the general population. Similar guidelines have also been developed by specific organ health associations to help their patient populations recover from disorders or prevent/delay clinical events and subsequent complications. However, there are no specific national and international guidelines to provide dietary and nutrient intake recommendations peri-transplantation. The complex nature of transplantation and in [...]

by Chawannuch Ruaengsri  , Miguel Alvarez-Cortes  , Marc Leon  , Manuel Quiroz-Flores  , Masafumi Shibata  and Yasuhiro Shudo

Received: 30 June 2025;  Published: 22 January 2026;  doi: 10.21926/obm.transplant.2601265

The increasing demand for organ transplantation has necessitated innovative strategies to maximize donor organ utilization, especially in donation after circulatory death (DCD) contexts. This article explores the integration of direct lung recovery with abdominal normothermic regional perfusion (A-NRP) to optimize organ preservation and expand the donor pool. A-NRP effectively mitigates warm ischemic injury, supporting the viability of both abdominal and thoracic organs. Our approach emphasizes meticulous surgical [...]

by Chawannuch Ruaengsri  , Marc Leon  , Miguel Alvarez-Cortes  , Manuel Quiroz-Flores  and Yasuhiro Shudo

Received: 30 June 2025;  Published: 21 January 2026;  doi: 10.21926/obm.transplant.2601264

To address the pressing shortage of donor lungs, Donation after Circulatory Death (DCD) transplantation has become a vital strategy for expanding the donor pool. Minimizing warm ischemic injury is crucial for optimizing organ viability and function. This review synthesizes current evidence on Normothermic Regional Perfusion (NRP) and Ex-Vivo Lung Perfusion (EVLP) in DCD lung transplantation. Analysis reveals their growing efficacy in minimizing ischemic damage, facilitating organ assessment, and expanding the trans [...]

by OBM Transplantation Editorial Office

Received: 03 January 2026;  Published: 04 January 2026;  doi: 10.21926/obm.transplant.2601263

The editors of OBM Transplantation would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2025. We greatly appreciate the contribution of expert reviewers, which is crucial to the journal's editorial process. We aim to recognize reviewer contributions through several mechanisms, of which the annual publication of reviewer names is one. Reviewers can download a certificate of recognition directly from our submission system. Additionally, reviewers can sign up to the Web [...]

by Garzain Bint e Attar  and Mohd. Ashif Khan

Received: 15 May 2025;  Published: 31 December 2025;  doi: 10.21926/obm.transplant.2504262

Bone grafting remains a cornerstone technique in orthopedic and reconstructive surgery, yet achieving successful graft integration continues to pose significant challenges, particularly in conditions such as osteoporosis, diabetes mellitus, and large bone defects. Traditional graft materials such as autografts, allografts, xenografts, and synthetics, often encounter limitations including immune rejection, poor vascularization, and insufficient osteogenic support. Emerging pharmacological strategies have shown promi [...]

by Chawannuch Ruaengsri  , Miguel Alvarez-Cortes  , Marc Leon  , Manuel Quiroz-Flores  , Masafumi Shibata  and Yasuhiro Shudo

Received: 30 June 2025;  Published: 30 December 2025;  doi: 10.21926/obm.transplant.2504261

Donation after circulatory death (DCD) offers a vital strategy to expand the donor lung pool; however, DCD lungs are uniquely susceptible to warm ischemic injury during procurement. This chapter reviews evidence-based and emerging donor management strategies aimed at mitigating ischemic damage and optimizing the suitability of DCD lungs for transplantation, encompassing hemodynamic and ventilatory optimization, bronchoscopic clearance, targeted pharmacological interventions, and strategies to minimize transfusion r [...]

by Vikash Chandra Mishra  , Dinesh Chandra  and Vimarsh Raina

Received: 15 July 2025;  Published: 25 November 2025;  doi: 10.21926/obm.transplant.2504260

Though the role of clinical histocompatibility testing is fundamental to successful transplant, systematic risk assessment and mitigation strategies remain underutilised in this domain. This review addresses risk identification, analysis, and control measures across the pre-analytical, analytical, and post-analytical phases of clinical histocompatibility testing, in line with international standards such as ISO 15189:2022. A structured, risk-based quality management system (QMS) is imperative for ensuring accurate [...]